BioNTech SE

LSE:0A3M Stock Report

Market Cap: US$29.2b

BioNTech Valuation

Is 0A3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A3M's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A3M's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A3M?

Key metric: As 0A3M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A3M. This is calculated by dividing 0A3M's market cap by their current revenue.
What is 0A3M's PS Ratio?
PS Ratio9.1x
Sales€3.04b
Market Cap€27.63b

Price to Sales Ratio vs Peers

How does 0A3M's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A3M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.6x
GNS Genus
1.6x4.0%UK£1.1b
OXB Oxford Biomedica
4.6x21.2%UK£451.8m
BVXP Bioventix
14.4xn/aUK£195.7m
GSK GSK
1.8x4.0%UK£54.8b
0A3M BioNTech
9.1x3.5%US$28.5b

Price-To-Sales vs Peers: 0A3M is expensive based on its Price-To-Sales Ratio (9.1x) compared to the peer average (5.6x).

Price to Sales Ratio vs Industry

How does 0A3M's PS Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.6x4.0%US$1.37b
TRX Tissue Regenix Group
1.7x15.1%US$52.64m
VRCI Verici Dx
1.9x78.8%US$8.11m
DEST Destiny Pharma
3.5x-171.4%US$5.85m
No more companies available in this PS range
0A3M 9.1xIndustry Avg. 8.1xNo. of Companies7PS01632486480+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A3M is expensive based on its Price-To-Sales Ratio (9.1x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0A3M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A3M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.1x
Fair PS Ratio6x

Price-To-Sales vs Fair Ratio: 0A3M is expensive based on its Price-To-Sales Ratio (9.1x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A3M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$121.00
US$136.03
+12.4%
9.6%US$172.05US$121.29n/a18
Nov ’25US$110.68
US$129.04
+16.6%
17.1%US$170.67US$89.21n/a18
Oct ’25US$119.65
US$123.86
+3.5%
19.6%US$170.83US$84.91n/a18
Sep ’25US$87.21
US$110.95
+27.2%
20.4%US$174.00US$86.49n/a18
Aug ’25US$81.26
US$111.62
+37.4%
20.3%US$171.09US$90.14n/a18
Jul ’25US$79.00
US$110.58
+40.0%
20.2%US$170.43US$89.21n/a18
Jun ’25US$100.29
US$111.66
+11.3%
20.4%US$171.87US$90.17n/a18
May ’25US$87.88
US$114.10
+29.8%
20.7%US$168.57US$89.10n/a18
Apr ’25US$92.57
US$117.29
+26.7%
23.6%US$186.95US$89.84n/a18
Mar ’25US$91.15
US$126.43
+38.7%
22.5%US$187.90US$98.86n/a17
Feb ’25US$94.36
US$126.87
+34.5%
22.4%US$187.19US$98.49n/a16
Jan ’25US$106.23
US$132.42
+24.7%
21.0%US$185.60US$100.28n/a16
Dec ’24US$98.12
US$134.68
+37.3%
23.0%US$198.93US$99.13US$118.4017
Nov ’24US$93.73
US$139.39
+48.7%
23.1%US$193.30US$101.82US$110.6817
Oct ’24US$109.98
US$146.17
+32.9%
22.9%US$196.79US$99.21US$119.6516
Sep ’24US$122.52
US$154.98
+26.5%
26.1%US$247.56US$98.60US$87.2117
Aug ’24US$106.58
US$162.25
+52.2%
24.7%US$251.54US$109.06US$81.2617
Jul ’24US$108.53
US$166.15
+53.1%
23.1%US$249.62US$108.22US$79.0016
Jun ’24US$104.61
US$161.13
+54.0%
23.4%US$245.51US$106.44US$100.2917
May ’24US$114.61
US$178.28
+55.6%
23.7%US$263.31US$128.00US$87.8817
Apr ’24US$123.60
US$183.95
+48.8%
22.2%US$260.34US$130.79US$92.5716
Mar ’24US$127.05
US$203.69
+60.3%
23.4%US$293.87US$139.63US$91.1515
Feb ’24US$140.91
US$211.95
+50.4%
23.5%US$306.00US$145.89US$94.3615
Jan ’24US$148.01
US$213.83
+44.5%
23.2%US$328.94US$152.71US$106.2315
Dec ’23US$168.10
US$209.30
+24.5%
22.4%US$317.11US$147.97US$98.1216

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y